LENSAR is expected to report Q3 2026 revenue of $14.30 million and a consensus EPS loss of $0.10, while the stock currently trades at $5.45 against a $11.52 average analyst target.

Investors are primarily focused on the installation rate of the ALLY Robotic Cataract Laser System and the conversion of its existing 13-unit backlog into recurring revenue.

While the company posted a surprise profit in the previous quarter, management has signaled that the third quarter typically experiences seasonal procedure softness and higher operating expenses.

The market is also watching for updates on international distributor relationships following the termination of the Alcon merger agreement.